Serum-Sphingosine-1-Phosphate Concentrations Are Inversely Associated with Atherosclerotic Diseases in Humans. - Wikidata - wikimedia - TriplyDB

Serum-Sphingosine-1-Phosphate Concentrations Are Inversely Associated with Atherosclerotic Diseases in Humans.

Serum-Sphingosine-1-Phosphate Concentrations Are Inversely Associated with Atherosclerotic Diseases in Humans.

http://www.wikidata.org/entity/Q36223845

about

Sphingosine Kinases and Sphingosine 1-Phosphate Receptors: Signaling and Actions in the Cardiovascular System.Sphingolipids and their metabolism in physiology and disease.Preanalytical Biases in the Measurement of Human Blood Sphingolipids.

P2860

Q41531207-E88D0FFC-82DD-4C19-8831-05D65275A5C8 Q47374235-5D4289B7-589A-4AEC-A019-4A206A8B4E6E Q53284180-6B781F94-545A-4720-8CAC-2A40E031CF4F

P2860

Serum-Sphingosine-1-Phosphate Concentrations Are Inversely Associated with Atherosclerotic Diseases in Humans.

http://www.wikidata.org/entity/Q36223845

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Serum-Sphingosine-1-Phosphate ...... osclerotic Diseases in Humans.

@ast

Serum-Sphingosine-1-Phosphate ...... osclerotic Diseases in Humans.

@en

type

label

Serum-Sphingosine-1-Phosphate ...... osclerotic Diseases in Humans.

@ast

Serum-Sphingosine-1-Phosphate ...... osclerotic Diseases in Humans.

@en

prefLabel

Serum-Sphingosine-1-Phosphate ...... osclerotic Diseases in Humans.

@ast

Serum-Sphingosine-1-Phosphate ...... osclerotic Diseases in Humans.

@en

P1433

Q36223845-2E43270E-182E-4487-BCBA-CB12958BAD59

P1476

Q36223845-6215D514-5F42-4DBE-8B88-F10D7128B204

P2093

Q36223845-150DA899-9ADC-43FB-BCA4-7DD50B3A881D

Q36223845-416123D5-6F68-4EA6-B0A0-70ADC3639707

Q36223845-623E581E-584A-456C-8011-DA57D389D077

Q36223845-6CB0F367-3C7F-43B5-814E-0726E585674C

Q36223845-706B97B4-CE11-4C56-BA28-B3816DEC125C

Q36223845-82E86767-7780-4027-AB3E-48FC298C2180

Q36223845-9212C92E-C44A-4C54-AA2C-C06F6390CD5D

Q36223845-BCB12410-322E-494B-9B07-B7FB053E2DC0

Q36223845-C077BBDA-233F-4315-AAAA-0CE3387E0600

Q36223845-C8C1D60B-14EB-4A80-A845-E9FDBF45B95C

P2860

Q36223845-000B6C8C-409C-4929-A97B-01E4C5CAEB13

Q36223845-0206BFEA-28D9-433A-8D97-A1C2052FEFDF

Q36223845-0F0BF4A7-1852-4181-B404-5CA020228127

Q36223845-1E2CD5E1-A17C-424E-ACEF-BBFC6E0EDBF0

Q36223845-1EDCBDA3-AE47-416C-BF33-83D6925E4F61

Q36223845-3288AAA2-8899-4AA4-9F47-1D94CD32E868

Q36223845-32F29E1B-59C5-44CD-926A-602356BD8219

Q36223845-399BD1CB-B80E-46AA-B590-B071AF15B878

Q36223845-3A766130-BE60-4C0A-B871-275A0802B89F

Q36223845-4201EE87-92D1-45A3-B327-0D19D7B78322

P304

Q36223845-BBEB29A6-4CD9-4F8A-94B4-1BDEC29D06BE

P31

Q36223845-1DC5F993-099D-45CB-BA32-D953B6E61269

P356

Q36223845-9EC54E1B-05CC-4E0F-9332-8DE2B9AE4E4B

P407

Q36223845-DF1292FF-A4CD-4ACC-911A-4B87E7A6E398

P433

Q36223845-46CFE196-F3F6-4950-AAA9-1F5F78014BEC

P478

Q36223845-CC80BD84-44BD-4AD5-AC8B-D3A5E9934C92

P50

Q36223845-2C508A25-E6B1-4EED-8075-EA2B00CF1A7B

Q36223845-D2DCC036-1F7C-4C0C-B86C-352102C35622

Q36223845-DAFC4C68-5854-41F9-A3E8-1A8152C01394

P577

Q36223845-B02B3661-823B-44A6-9419-FA96B7D96D73

P698

Q36223845-C8FB4776-7997-4117-9BE8-8E2249BA0808

P921

Q36223845-889FA75E-C6BF-4E4D-B54B-1E6AED20B7EF

P932

Q36223845-F803AF72-EE0B-4E2A-BE0F-AEF4202A7F65

P356

JOURNAL.PONE.0168302

P1433

P1476

Serum-Sphingosine-1-Phosphate ...... osclerotic Diseases in Humans.

@en

P2093

E Sebastian Debus

http://www.w3.org/2001/XMLSchema#string

Edzard Schwedhelm

http://www.w3.org/2001/XMLSchema#string

Eileen Mudersbach

http://www.w3.org/2001/XMLSchema#string

Gerhard Schoen

http://www.w3.org/2001/XMLSchema#string

Guenter Daum

http://www.w3.org/2001/XMLSchema#string

Irina Soltau

http://www.w3.org/2001/XMLSchema#string

Maria Geffken

http://www.w3.org/2001/XMLSchema#string

Markus Geissen

http://www.w3.org/2001/XMLSchema#string

Martin S Winkler

http://www.w3.org/2001/XMLSchema#string

Sven Peine

http://www.w3.org/2001/XMLSchema#string

P2860

Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement

Atherosclerosis — An Inflammatory Disease

Intracoronary imaging for detecting vulnerable plaque

Non-invasive molecular imaging of vulnerable atherosclerotic plaques

Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection

Vascular endothelium as a contributor of plasma sphingosine 1-phosphate.

Sphingosine 1-phosphate release from platelets during clot formation: close correlation between platelet count and serum sphingosine 1-phosphate concentration.

The immune system in atherosclerosis.

Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.

Sphingosine 1-phosphate in acute dengue infection

P304

e0168302

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0168302

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Axel Larena-Avellaneda

Edzard Schwedhelm

P577

2016-12-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27973607

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

5156421

http://www.w3.org/2001/XMLSchema#string